Paper12790806
Adipose thyrotrophin receptor expression is elevated in Graves' and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo.
Starkey KJ and 5 others. J Mol Endocrinol, 2003. Cited by 69 papers, by iCite.
Cite this record
ConductScience Library. Adipose thyrotrophin receptor expression is elevated in Graves' and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo. Papers, record 12790806. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/12790806
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Adipose thyrotrophin receptor expression is elevated in Graves' and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adipose Tissue | Major topic |
| Graves Disease | Major topic |
| Receptors, Thyrotropin | Major topic |
| Animals | |
| Base Sequence | |
| DNA Primers | |
| Humans | |
| Mice | |
| Mice, Inbred BALB C |
Source PubMed
Cited by42
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 69 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41837138 | Maraviroc attenuates orbital remodeling, inflammation, and lipid dysregulation in a murine model of thyroid eye disease associated with Graves' disease. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/41837138 | PubMed |
| 41728592 | The therapeutic revolution in thyroid eye disease: from orbital radiotherapy to teprotumumab and AI. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/41728592 | PubMed |
| 40605078 | Thyroid hormone signaling in ocular development and diseases. | Biol Res | 2025 | https://conductscience.org/library/papers/40605078 | PubMed |
| 38273183 | Safety of non-standard regimen of systemic steroid therapy in patients with Graves' orbitopathy: a single-centre experience. | Pharmacol Rep | 2024 | https://conductscience.org/library/papers/38273183 | PubMed |
| 37870639 | TSH receptor autoantibody levels post-total thyroidectomy in Graves' ophthalmopathy: a meta-analysis. | Langenbecks Arch Surg | 2023 | https://conductscience.org/library/papers/37870639 | PubMed |
| 37435490 | Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease. | Front Endocrinol (Lausanne) | 2023 | https://conductscience.org/library/papers/37435490 | PubMed |
| 37080243 | Thyrotropin Receptor Autoantibody Assessment in Thyroid Eye Disease: Does the Assay Type Matter? | Korean J Ophthalmol | 2023 | https://conductscience.org/library/papers/37080243 | PubMed |
| 35903283 | The Mysterious Universe of the TSH Receptor. | Front Endocrinol (Lausanne) | 2022 | https://conductscience.org/library/papers/35903283 | PubMed |
| 35566351 | Different Effects of Cigarette Smoke, Heated Tobacco Product and E-Cigarette Vapour on Orbital Fibroblasts in Graves' Orbitopathy; a Study by Real Time Cell Electronic Sensing. | Molecules | 2022 | https://conductscience.org/library/papers/35566351 | PubMed |
| 34899596 | Orbital Signaling in Graves' Orbitopathy. | Front Endocrinol (Lausanne) | 2021 | https://conductscience.org/library/papers/34899596 | PubMed |
| 34889904 | Expression of Endogenous Putative TSH Binding Protein in Orbit. | Curr Issues Mol Biol | 2021 | https://conductscience.org/library/papers/34889904 | PubMed |
| 31889140 | New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. | Nat Rev Endocrinol | 2020 | https://conductscience.org/library/papers/31889140 | PubMed |
| 31844169 | Fibrosis in dysthyroid eye disease. | Eye (Lond) | 2020 | https://conductscience.org/library/papers/31844169 | PubMed |
| 31781640 | Immunological Aspects of Graves' Ophthalmopathy. | Biomed Res Int | 2019 | https://conductscience.org/library/papers/31781640 | PubMed |
| 30414981 | Molecular biomarkers of Graves' ophthalmopathy. | Exp Mol Pathol | 2019 | https://conductscience.org/library/papers/30414981 | PubMed |
| 29320711 | Anatomical, Physiological, and Functional Diversity of Adipose Tissue. | Cell Metab | 2018 | https://conductscience.org/library/papers/29320711 | PubMed |
| 28539287 | [Calculation of orbital fat volumes for determining treatment timing for thyroid- associated ophthalmopathy]. | Nan Fang Yi Ke Da Xue Xue Bao | 2017 | https://conductscience.org/library/papers/28539287 | PubMed |
| 28469599 | The Role of Thyrotropin Receptor Activation in Adipogenesis and Modulation of Fat Phenotype. | Front Endocrinol (Lausanne) | 2017 | https://conductscience.org/library/papers/28469599 | PubMed |
| 24302624 | A modified ELISA accurately measures secretion of high molecular weight hyaluronan (HA) by Graves' disease orbital cells. | Endocrinology | 2014 | https://conductscience.org/library/papers/24302624 | PubMed |
| 24286160 | Propylthiouracil prevents cutaneous and pulmonary fibrosis in the reactive oxygen species murine model of systemic sclerosis. | Arthritis Res Ther | 2013 | https://conductscience.org/library/papers/24286160 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| TSHR | 7253 | PubTator's text mining | https://conductscience.org/library/genes/7253 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/12790806
GET https://conductscience.org/api/papers/v1/12790806/cited_by?page=2